Manal M. Hassan

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2025

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2025

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2024

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2024

Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer (PC). Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for PC. Methods: Data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium (PanScan; cases n=5090, controls n=8733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n=4,163, controls n=3,792) were analyzed. We used data on 68 genetic variants with four different MR methods (inverse variance weighting [IVW], MR-Egger, simple median, and penalized weighted median) separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and PC risk, using logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and PC risk in the PanScan or PanC4 samples (e.g., PanScan, IVW OR=1.04, 95% CI: 0.88-1.22, MR-Egger OR=0.89, 95% CI: 0.65-1.21; PanC4, IVW OR=1.07, 95% CI: 0.90-1.27, MR-Egger OR=0.93, 95% CI: 0.67-1.28). None of the four MR methods indicated an association between genetically predicted NAFLD and PC risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with PC risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and PC might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and PC.

Year:

2024

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2024

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2024

Background: It is estimated that 6% to 20% of all cholangiocarcinoma (CCA) diagnoses are explained by primary sclerosing cholangitis (PSC), but the underlying risk factors in the absence of PSC are unclear. We examined associations of different risk factors with intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) in the United States. Methods: We conducted a case–control study of 121 patients with ECC and 308 patients with ICC treated at MD Anderson Cancer Center between May 2014 and March 2020, compared with 1,061 healthy controls. Multivariable logistic regression analysis was applied to estimate the adjusted OR (AOR) and 95% confidence interval (CI) for each risk factor. Results: Being Asian, diabetes mellitus, family history of cancer, and gallbladder stones were associated with higher odds of developing ICC and ECC. Each 1-unit increase in body mass index in early adulthood (ages 20–40 years) was associated with a decrease in age at diagnosis of CCA (6.7 months, P < 0.001; 6.1 months for ICC, P = 0.001; 8.2 months for ECC, P = 0.007). A family history of cancer was significantly associated with the risk of ICC and ECC development; the AORs (95% CI) were 1.11 (1.06–1.48) and 1.32 (1.01–2.00) for ICC and ECC, respectively. Conclusions: In this study, early adulthood onset of obesity was significantly associated with CCA and may predict early diagnosis at younger age than normal weight individuals. Impact: The study highlights the association between obesity and CCA, independent of PSC. There is a need to consider the mechanistic pathways of obesity in the absence of fatty liver and cirrhosis.

Year:

2023

Collaborators (32)

Rayjean Hung

University of Toronto

CANADA
View details

Neal Freedman

Branch Chief

National Cancer Institute

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Ian M. Thompson

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Anne Tjonneland

Professor

Københavns Universitet

DENMARK
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Miquel Porta

-

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Kari Rabe

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Stephen Chanock

National Institutes of Health

UNITED STATES
View details

Alison Klein

Professor

-

UNITED STATES
View details

Federico Canzian

Group Leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Herbert Yu

Researcher/Professor

University of Hawaii at Manoa

UNITED STATES
View details

Martijn C.G.J. Brouwers

-

NETHERLANDS
View details

Thilo Hackert

University Hospital Heidelberg

GERMANY
View details

Elio Riboli

Professor of Cancer Epidemiology

Imperial College London

UNITED KINGDOM
View details

Rachael Solomon

Senior Eoidemiologist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Jean Wactawki-Wende

Dean, Suny Distinguished Professor

University at Buffalo

UNITED STATES
View details

Malin Sund

Professor/Consultant

University of Helsinki

FINLAND
View details

Loic Le Marchand

Professor

University of Hawaii

UNITED STATES
View details

Donghui Li

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anne Zeleniuch-Jacquotte

Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Alan Arslan

Associate Professor

NYU Langone Medical Center

UNITED STATES
View details

Nuria Malats

Group Leader

Centro Nacional de Investigaciones Oncológicas

SPAIN
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Veronica Setiawan

Associate Professor

University of Southern California

UNITED STATES
View details

Charles Kooperberg

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Graham Giles

Head of Research

-

AUSTRALIA
View details

Manolis Kogevinas

Senior Researcher

Barcelona Institute for Global Health

SPAIN
View details